Ainos, Inc. (AIMD) News
Track canonical SquawkNews coverage tagged to AIMD, Ainos, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Ainos, Inc. (AIMD) Delivers 1,400 AI Nose Units Under $2.1M ASE Deal
Ainos completed delivery of 1,400 AI Nose systems to ASE under a $2.1M, three-year agreement, enabling revenue recognition beginning in Q3 2026. The parties are discussing a larger second-phase deployment under an existi
EARNINGS | Sep 29, 2026, 12:01 PM UTC
L
Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract
Preparations underway for a larger-scale second-phase deployment specified in the existing MOU, building on first-phase deployment experienceAdvanced packaging deployment marks a major step for Ainos' Chemical Intelligen
NEWS | Sep 29, 2026, 12:01 PM UTC
L
Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence
Initial license payment tied to near-term contractual delivery; additional payment opportunities may arise during development, before drug approvalPartner assumes assigned clinical and regulatory funding and execution, r
NEWS | Sep 28, 2026, 12:08 PM UTC
L
Ainos Grants Global VELDONA License to BioPhoenix; Upfront $600,000, Fees Up to $10 Million
Ainos entered into a Global Exclusive License Agreement with BioPhoenix covering its VELDONA low-dose oral interferon alpha platform for Sjögren’s Disease and thrombocytopenia. The worldwide, transferable license allows
NEWS | Sep 28, 2026, 12:05 PM UTC
L
Ainos, Inc. (AIMD) Signs VELDONA License With Potential $10M Framework
Ainos signed a VELDONA license with BioPhoenix, outlining a potential $10M collaboration framework. BioPhoenix will fund and execute development for two initial indications; the $10M is conditional and excludes developme
NEWS | Sep 24, 2026, 12:03 PM UTC
L
Ainos and BioPhoenix Sign VELDONA License Agreement, Establishing a Potential $10 Million Collaboration Framework
Partner-funded development marks an important milestone for VELDONA, with BioPhoenix funding and advancing clinical and regulatory development for two initial indicationsDevelopment funding is additional to the framework
NEWS | Sep 24, 2026, 12:02 PM UTC
L
Ainos secures three Japanese robotics patents for chemical perception
Ainos says new patents cover electronic nose integration with robotics. It also cites a portfolio of 124 patent assets worldwide across chips, sensing architectures, chemical molecules and real-world applications.
EQUITY | Sep 09, 2026, 12:01 PM UTC
L
AIMD Expands Smell AI
Ainos expands smell AI into patient-level breath intelligence, according to VASRO Research
EQUITY | Jun 22, 2026, 01:02 PM UTC